# HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

> **NCT05787418** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Huahui Health** · enrollment: 1200 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** HH-120 Nasal Spray
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05787418
- **Lead sponsor:** Huahui Health
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-03-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-04-01
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05787418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05787418, "HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05787418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*